The prevention effect of Limosilactobacillus reuteri on acute kidney injury by regulating gut microbiota
Microbiology and Immunology · 2024-07 · 68 (7) · 213-223
DOI: 10.1111/1348-0421.13130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, online erschienen am 15.05.2024. Verfasst von Zhan Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Huadong Medical Institute of Biotechniques, Nanjing, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Limosilactobacillus reuteri, Probiotics, Acute Kidney Injury. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key R&D Program of China.
Abstract (Originalsprache)
Acute kidney injury (AKI) has considerably high morbidity and mortality but we do not have proper treatment for it. There is an urgent need to develop new prevention or treatment methods. Gut microbiota has a close connection with renal diseases and has become the new therapy target for AKI. In this study, we found the oral administration of the probiotic Limosilactobacillus reuteri had a prevention effect on the AKI induced by lipopolysaccharide (LPS). It reduced serum concentration of creatinine and urea nitrogen and protected the renal cells from necrosis and apoptosis. Meanwhile, L. reuteri improved the gut barrier function, which is destroyed in AKI, and modulated the gut microbiota and relevant metabolites. Compared with the LPS group, L. reuteri increased the proportion of Proteobacteria and reduced the proportion of Firmicutes, changing the overall structure of the gut microbiota. It also influenced the fecal metabolites and changed the metabolite pathways, such as tyrosine metabolism, pentose and glucuronate interconversions, galactose metabolism, purine metabolism, and insulin resistance. These results showed that L. reuteri is a potential therapy for AKI as it helps in sustaining the gut barrier integrity and modulating gut microbiota and related metabolites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huadong Medical Institute of Biotechniques, Nanjing, China.
- Department of Nephrology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China.
- Binzhou Medical University, Yantai, China.
- Air Force Hospital of Eastern Theater, Nanjing, China.
- School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
Förderung
- National Key R&D Program of China
Zitieren
APA
Yang, Z., Ni, J., Sun, X., Cui, Q., Zhang, X., Zhang, M., Zhu, X., Wu, Z., Tang, C., Zhu, J., Mao, H., Liu, K., Wang, C., Xing, C., & Zhu, J. (2024). The prevention effect of Limosilactobacillus reuteri on acute kidney injury by regulating gut microbiota. Microbiology and Immunology, 68(7), 213-223. https://doi.org/10.1111/1348-0421.13130
Vancouver
Yang Z, Ni J, Sun X, Cui Q, Zhang X, Zhang M, et al. The prevention effect of Limosilactobacillus reuteri on acute kidney injury by regulating gut microbiota. Microbiology and Immunology. 2024;68(7):213-223. doi:10.1111/1348-0421.13130
BibTeX
@article{Yang2024,
author = {Yang, Zhan and Ni, Juan and Sun, Xuewei and Cui, Qian and Zhang, Xinrui and Zhang, Mingyan and Zhu, Xiaojing and Wu, Zihan and Tang, Chengliang and Zhu, Jingfeng and Mao, Huijuan and Liu, Kang and Wang, Chunhui and Xing, Changying and Zhu, Jin},
title = {The prevention effect of Limosilactobacillus reuteri on acute kidney injury by regulating gut microbiota},
journal = {Microbiology and Immunology},
year = {2024},
volume = {68},
number = {7},
pages = {213--223},
doi = {10.1111/1348-0421.13130}
}
EUVIMED